Cht11 Antibody

What is CHST11 and why is it important in research?

CHST11, also known as chondroitin 4-sulfotransferase-11, is an enzyme involved in the sulfation and presentation of chondroitin in human cells. The gene is highly expressed in aggressive breast cancer cells and significantly less so in less aggressive cancer cell lines . Research has demonstrated that CHST11 plays a critical role in the production of P-selectin ligands, which are involved in cancer metastasis through cell adhesion mechanisms. The importance of CHST11 in research stems from its overexpression in tumor-containing clinical tissue specimens compared with normal tissues, making it a potential biomarker and therapeutic target .

Methodological approach: To study CHST11 expression, researchers commonly use quantitative real-time PCR (qRT-PCR) to monitor expression levels across different cell lines. This approach allows for precise quantification of gene expression and comparison between different cancer phenotypes, ranging from minimally aggressive (e.g., MCF7) to highly metastatic (e.g., MDA-MB-231, MDA-MET) .

How do researchers validate CHST11 antibody specificity?

Validation of CHST11 antibody specificity typically involves the following methodological steps:

• siRNA knockdown experiments: Treating cells with CHST11-specific siRNA and observing the corresponding decrease in antibody binding. For example, in MDA-MB-231 cells, transfection with CHST11 siRNA significantly reduced CHST11 mRNA levels and corresponding antibody binding .

• Western blot analysis: Checking for a single band at the expected molecular weight of CHST11.

• Immunohistochemistry with positive and negative controls: Using known CHST11-positive and CHST11-negative tissues to confirm staining patterns.

• Knockout cell line testing: Using CHST11 knockout cell lines (e.g., CRISPR-Cas9 generated) to confirm absence of antibody binding. As seen in research with A375 Chst11 KO cells compared to A375 WT cells .

• Correlation with functional assays: Verifying that antibody binding correlates with known CHST11-mediated functions such as P-selectin binding .

How can CHST11 antibodies be utilized in cancer research protocols?

CHST11 antibodies serve multiple purposes in cancer research:

• Expression profiling across cancer types: Immunohistochemistry using CHST11 antibodies helps identify cancer types with elevated CHST11 expression. Research has shown CHST11 is overexpressed in clinical breast cancer tissues, with approximately 3.2-fold higher expression in tumor tissue compared to normal tissue (P < 0.02) .

• Metastasis research: Since CHST11 is involved in producing chondroitin sulfate, which functions as a P-selectin ligand, CHST11 antibodies can be used to study the relationship between chondroitin sulfate expression and metastatic potential .

• Development of targeted therapies: Chimeric antibody fragments targeting CHST11-produced chondroitin sulfate chains have shown high-affinity binding (1.2 to 7.4 nM) to oncofetal chondroitin sulfate (ofCS) without binding to HSPG .

• Therapeutic antibody development: CHST11 antibodies have been used to develop antibody-drug conjugates (ADCs). For example, ABD-C9 scFv ADC has been tested in xenograft models with significant tumor reduction compared to controls .

Methodological considerations should include appropriate antibody dilutions (1:200-1:500 for IHC as recommended by manufacturers) , proper tissue preparation, and inclusion of appropriate controls.

What techniques allow researchers to investigate the relationship between CHST11 expression and P-selectin binding?

Several methodological approaches can be used to investigate this relationship:

• Flow cytometry: Measuring the binding of recombinant P-selectin to cells with different levels of CHST11 expression. Research has shown a statistically significant correlation (r = 0.85, P < 0.0001) between CHST11 expression and P-selectin binding .

• siRNA knockdown: Inhibiting CHST11 expression using siRNA and measuring the effect on P-selectin binding. In MDA-MB-231 cells, transfection with CHST11 siRNA significantly reduced the mean fluorescence intensity for P-selectin binding (P ≤0.001) .

• Enzyme treatments: Treating cells with chondroitinase ABC (chABC) to enzymatically remove chondroitin sulfate and assess the impact on P-selectin binding.

• Correlation analysis: Statistically analyzing the relationship between CHST11 expression levels and P-selectin binding across multiple cell lines. This revealed that only CHST11 showed a statistically significant correlation with P-selectin binding among various sulfotransferases tested .

(Table derived from data in search result )

How can researchers overcome variability in CHST11 antibody performance across different experimental systems?

Variability in antibody performance can significantly impact research outcomes. To address this challenge:

• Standardize validation protocols: Employ multiple validation techniques including western blot, immunohistochemistry, and flow cytometry to confirm antibody specificity.

• Optimize antibody concentrations: Titrate antibody concentrations for each application. For immunohistochemistry, dilutions of 1:200-1:500 have been recommended .

• Consider multiple antibody clones: Different antibody clones may perform differently across applications. Testing multiple antibodies against CHST11 can help identify the most reliable for your specific application.

• Use appropriate negative controls: Include CHST11 knockdown or knockout samples. For example, comparing binding in wild-type A375 cells versus A375 Chst11 KO cells can verify antibody specificity .

• Cross-validate with gene expression: Correlate antibody staining with CHST11 mRNA levels measured by qRT-PCR to ensure consistency between protein and gene expression data.

• Careful sample preparation: Standardize fixation protocols for immunohistochemistry applications, as different fixation methods can affect epitope accessibility.

What are effective strategies for analyzing CHST11's role in metastasis using antibody-based approaches?

To investigate CHST11's role in metastasis, researchers can implement these methodological strategies:

• In vivo metastasis models with CHST11 modulation:

  • Generate CHST11 knockdown or knockout cell lines

  • Inject these cells into animal models

  • Compare metastatic potential to wild-type cells

  • Use CHST11 antibodies to confirm expression status in resultant tumors

• Antibody blocking experiments:

  • Utilize CHST11 antibodies to block function in vitro

  • Assess impact on adhesion, migration, and invasion abilities

  • For example, enzymatic removal of tumor-cell surface CS-GAGs significantly inhibited lung colonization of the 4T1 murine mammary cell line (P = 0.0002)

• Correlation studies in patient samples:

  • Analyze CHST11 expression using antibodies in primary tumors versus metastatic lesions

  • Correlate expression with clinical outcomes and metastatic status

  • Research has shown CHST11 was elevated 1.8-fold (P = 0.034) in tumor tissue compared to normal tissue among 15 subjects

• Combination with P-selectin studies:

  • Use flow cytometry to simultaneously detect CHST11 expression and P-selectin binding

  • Investigate if P-selectin binding correlates with metastatic potential

  • In studies examining breast cancer cell lines of increasing aggressiveness (MCF7 < MDA-MB-468 < MDA-MB-231 = MDA-MET), CHST11 expression directly correlated with metastatic potential

How can CHST11 antibodies be utilized in the development of targeted cancer therapies?

CHST11 antibodies have significant potential for developing targeted cancer therapies through several methodological approaches:

• Antibody-drug conjugates (ADCs):

  • Using CHST11 antibodies as targeting vehicles to deliver cytotoxic payloads

  • Research demonstrated that ABD-C9 scFv ADC significantly reduced tumor growth in xenograft models compared to controls

  • This approach allows specific targeting of cancer cells with elevated CHST11 expression

• Chimeric antigen receptor T-cell (CAR-T) therapy:

  • Similar to approaches using other antibodies (e.g., 3H11), CHST11 antibodies could be used to design CAR-T cells

  • The single-chain variable fragment (scFV) from CHST11 antibodies could be incorporated into CAR-T constructs

  • This approach may allow targeting of tumors expressing high levels of CHST11 or its products

• Therapeutic antibodies blocking CS-mediated interactions:

  • CHST11 antibodies could be used to block the function of chondroitin sulfate in promoting metastasis

  • This approach targets the products of CHST11 activity rather than the enzyme itself

  • Research has shown that targeting CS-GAGs and their biosynthetic pathways like CHST11 are promising targets for anti-metastatic therapies

• Active learning approaches for optimizing antibody specificity:

  • Implementing active learning strategies for improving antibody-antigen binding specificity

  • These computational methods help select which antibody-antigen pairs to test experimentally

  • Both model-based and diversity-based approaches can maximize the informativeness of selected pairs for testing

What methodological approaches can resolve contradictory findings about CHST11 expression across different cancer types?

To address contradictory findings about CHST11 expression, researchers should consider these methodological solutions:

• Standardized tissue processing and analysis:

  • Implement consistent protocols for tissue collection, preservation, and processing

  • Use automated staining platforms to reduce technical variability

  • Employ digital pathology for quantitative analysis of antibody staining

• Multi-omic analysis:

  • Correlate CHST11 protein expression (via antibody staining) with mRNA expression

  • Integrate with genomic data to identify potential genetic alterations affecting CHST11

  • Include epigenetic analysis to understand regulatory mechanisms

• Cancer subtype stratification:

  • Analyze CHST11 expression within molecular subtypes of cancers

  • For example, in breast cancer research, gene overexpression was detected in both ER-positive and ER-negative samples, but the majority of specimens with increased expression of CHST11 (seven out of eight), were HER2-neu-negative

  • This stratification may reveal patterns not apparent in pooled analyses

• Spatial analysis within tumor microenvironment:

  • Utilize multiplex immunohistochemistry to examine CHST11 expression in relation to other markers

  • Analyze expression patterns in tumor core versus invasive front

  • As shown in research, different antibody fragments exhibited different binding profiles to epithelial, mesenchymal, and hematological cell lines

• Functional validation studies:

  • Move beyond correlative studies to knockdown/knockout approaches

  • Validate the role of CHST11 in different cancer types through functional assays

  • For example, siRNA inhibition of CHST11 expression resulted in inhibition of CS-A production and P-selectin binding

What are the optimal conditions for CHST11 antibody use in different experimental applications?

To achieve optimal results with CHST11 antibodies across different applications, consider these methodological details:

Immunohistochemistry (IHC):

• Recommended dilution: 1:200-1:500

• Optimal fixation: 10% neutral buffered formalin

• Antigen retrieval method: Citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Detection system: Use high-sensitivity detection systems such as polymer-based methods

• Controls: Include known CHST11-positive tissues and negative controls (omitting primary antibody)

Western Blotting:

• Sample preparation: Use RIPA buffer with protease inhibitors

• Protein loading: 20-50 μg of total protein per lane

• Blocking solution: 5% non-fat dry milk in TBST

• Primary antibody incubation: Overnight at 4°C with gentle agitation

• Secondary antibody: HRP-conjugated anti-species IgG

• Detection: Enhanced chemiluminescence (ECL) systems

Flow Cytometry:

• Cell preparation: Single-cell suspension, fixed with 2-4% paraformaldehyde

• Permeabilization (for intracellular staining): 0.1% Triton X-100 or commercial permeabilization buffer

• Antibody concentration: Titrate to determine optimal concentration

• Incubation time: 30-60 minutes at room temperature or 4°C

• Secondary detection: FITC-conjugated anti-species IgG or directly conjugated primary antibodies

• Controls: Include isotype controls and CHST11 knockdown cells

Immunoprecipitation:

• Lysis buffer: NP-40 or RIPA buffer with protease inhibitors

• Antibody amount: 2-5 μg per 500 μg of total protein

• Pre-clearing: Incubate lysate with Protein A/G beads before adding antibody

• Incubation: Overnight at 4°C with rotation

• Washing: At least 3-5 washes with lysis buffer

• Elution: SDS sample buffer at 95°C for 5 minutes

How can researchers design experiments to determine the specificity of CHST11 antibodies for targeting chondroitin sulfate in therapeutic applications?

To validate CHST11 antibody specificity for therapeutic targeting of chondroitin sulfate, implement these methodological approaches:

• Enzymatic digestion controls:

  • Treat samples with chondroitinase ABC (chABC) to remove chondroitin sulfate

  • Compare antibody binding before and after enzyme treatment

  • This approach validated CS specificity in studies of ofCS-targeting antibody fragments

• Competitive binding assays:

  • Pre-incubate antibodies with purified chondroitin sulfate of different sulfation patterns

  • Assess whether pre-incubation blocks binding to cellular targets

  • This helps determine specificity for particular CS subtypes (CS-A, CS-E, etc.)

• Cell line panel screening:

  • Test antibody binding across diverse cell lines with varying levels of CHST11 expression

  • Include epithelial, mesenchymal, and hematological cell lines

  • For example, some antibody fragments bound all tested cell lines while others showed preferential binding to specific cell types

• Cross-reactivity assessment:

  • Test binding to other glycosaminoglycans (heparan sulfate, dermatan sulfate, etc.)

  • Ensure specificity for chondroitin sulfate over related molecules

  • Research showed some antibody fragments exhibited high specificity to CS without any binding to HS

• Functional blocking studies:

  • Determine if antibodies block P-selectin binding to cells

  • Assess impact on cell adhesion and migration

  • Studies have shown that blocking CHST11 expression with siRNA inhibited CS-A expression and P-selectin binding

• In vivo specificity:

  • Conduct biodistribution studies in animal models

  • Compare tumor uptake versus normal tissue accumulation

  • In xenograft models, antibody-based therapies targeting CS have shown efficacy in reducing tumor burden

By implementing these methodological approaches, researchers can confidently establish the specificity of CHST11 antibodies for therapeutic applications targeting chondroitin sulfate in cancer and other diseases.